AR078763A1 - Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas - Google Patents
Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistasInfo
- Publication number
- AR078763A1 AR078763A1 ARP100103911A ARP100103911A AR078763A1 AR 078763 A1 AR078763 A1 AR 078763A1 AR P100103911 A ARP100103911 A AR P100103911A AR P100103911 A ARP100103911 A AR P100103911A AR 078763 A1 AR078763 A1 AR 078763A1
- Authority
- AR
- Argentina
- Prior art keywords
- dom1h
- tnfr1
- antagonists
- variable domains
- single variable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente se refiere a dominios variables sencillos de anticuerpo anti-TNFR1 (dAb estables en almacenamiento, antagonistas y ligandos multiespecíficos, así como a procedimientos y usos de los mismos. Los polipéptidos, dominios variables sencillos de anticuerpo (dAb), antagonistas y ligandos multiespecíficos anti-TNFR1 son utiles para tratar y/o prevenir una enfermedad inflamatoria, tal como artritis o enfermedad pulmonar obstructiva cronica (EPOC), así como para administracion pulmonar, administracion oral, liberacion en los pulmones y liberacion en tracto GI de un paciente. Reivindicacion 1: Un dominio variable sencillo de inmunoglobulina del receptor anti-TNFalfa de tipo 1 (TNFR1; p55) que comprende una secuencia de aminoácidos que es al menos un 95, 96, 97, 98 o 99% idéntica (o 100% idéntica) a la secuencia de aminoácidos de DOM1h-574-188, DOM1h-574-189, DOM1h-574-190, DOM1h-574-191, DOM1h-574-192, DOM1h-574-195, DOM1h-574-196, DOM1h-574-201, DOM1h-574-202, DOM1h-574-203, DOM1h-574-204, DOM1h-574-205, DOM1h-574-206, DOM1h-574-207, DOM1h-574-208, DOM1h-574-209, DOM1h-574-211, DOM1h-574-212, DOM1h-574-213 o DOM1h-574-214, en el que el dominio variable sencillo tiene una DO320 <1,0, <0,9, <0,8, <0,7, <0,6, <0,5, o <0,4 tras la incubacion en PBS a 40°C durante 40 horas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25523509P | 2009-10-27 | 2009-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078763A1 true AR078763A1 (es) | 2011-11-30 |
Family
ID=43382391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100103911A AR078763A1 (es) | 2009-10-27 | 2010-10-25 | Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas |
Country Status (26)
Country | Link |
---|---|
US (1) | US20150210767A1 (es) |
EP (1) | EP2493504B1 (es) |
JP (1) | JP2013507978A (es) |
KR (1) | KR20120101417A (es) |
CN (1) | CN102686239B (es) |
AR (1) | AR078763A1 (es) |
AU (1) | AU2010311640B2 (es) |
BR (1) | BR112012010114A2 (es) |
CA (1) | CA2777312A1 (es) |
CL (1) | CL2012001055A1 (es) |
CO (1) | CO6612254A2 (es) |
CR (1) | CR20120197A (es) |
DO (1) | DOP2012000113A (es) |
EA (1) | EA022898B1 (es) |
ES (1) | ES2552177T3 (es) |
IL (1) | IL218860A0 (es) |
MA (1) | MA33758B1 (es) |
MX (1) | MX2012005024A (es) |
NZ (1) | NZ599114A (es) |
PE (1) | PE20121564A1 (es) |
SG (1) | SG10201500274TA (es) |
TW (1) | TW201125877A (es) |
UA (1) | UA107200C2 (es) |
UY (1) | UY32969A (es) |
WO (1) | WO2011051217A1 (es) |
ZA (1) | ZA201203052B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012517818A (ja) * | 2009-02-19 | 2012-08-09 | グラクソ グループ リミテッド | 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
EP2721066A1 (en) * | 2011-06-17 | 2014-04-23 | Glaxo Group Limited | Tumour necrosis factor receptor 1 antagonists |
WO2014118220A1 (en) * | 2013-01-31 | 2014-08-07 | Glaxo Group Limited | Method of producing a protein |
WO2015104322A1 (en) | 2014-01-09 | 2015-07-16 | Glaxosmithkline Intellectual Property Development Limited | Treatment of inflammatory diseases with non-competitive tnfr1 antagonists |
BR112018070452A2 (pt) * | 2016-04-05 | 2019-02-05 | Baliopharm Ag | um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico |
CA3193273A1 (en) | 2020-08-27 | 2022-03-03 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
CN114699533B (zh) * | 2022-05-06 | 2023-05-09 | 郑州大学 | 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
DE69838521T2 (de) | 1997-07-07 | 2008-05-21 | Medical Research Council | Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
ATE328906T1 (de) | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
WO2004101790A1 (en) | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
CN101084014A (zh) * | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
KR20100018040A (ko) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
EP3656788A3 (en) * | 2009-02-19 | 2020-07-29 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
JP2012517818A (ja) * | 2009-02-19 | 2012-08-09 | グラクソ グループ リミテッド | 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
-
2010
- 2010-10-25 TW TW099136369A patent/TW201125877A/zh unknown
- 2010-10-25 UA UAA201204796A patent/UA107200C2/uk unknown
- 2010-10-25 CA CA2777312A patent/CA2777312A1/en not_active Abandoned
- 2010-10-25 AR ARP100103911A patent/AR078763A1/es unknown
- 2010-10-25 BR BR112012010114A patent/BR112012010114A2/pt not_active IP Right Cessation
- 2010-10-25 NZ NZ599114A patent/NZ599114A/en not_active IP Right Cessation
- 2010-10-25 EP EP10774177.9A patent/EP2493504B1/en active Active
- 2010-10-25 UY UY0001032969A patent/UY32969A/es not_active Application Discontinuation
- 2010-10-25 KR KR1020127013723A patent/KR20120101417A/ko not_active Application Discontinuation
- 2010-10-25 JP JP2012535767A patent/JP2013507978A/ja active Pending
- 2010-10-25 CN CN201080059618.5A patent/CN102686239B/zh not_active Expired - Fee Related
- 2010-10-25 PE PE2012000560A patent/PE20121564A1/es not_active Application Discontinuation
- 2010-10-25 AU AU2010311640A patent/AU2010311640B2/en not_active Ceased
- 2010-10-25 SG SG10201500274TA patent/SG10201500274TA/en unknown
- 2010-10-25 WO PCT/EP2010/066046 patent/WO2011051217A1/en active Application Filing
- 2010-10-25 MX MX2012005024A patent/MX2012005024A/es not_active Application Discontinuation
- 2010-10-25 ES ES10774177.9T patent/ES2552177T3/es active Active
- 2010-10-25 EA EA201290172A patent/EA022898B1/ru not_active IP Right Cessation
-
2012
- 2012-03-27 IL IL218860A patent/IL218860A0/en unknown
- 2012-03-29 CO CO12053463A patent/CO6612254A2/es unknown
- 2012-04-18 DO DO2012000113A patent/DOP2012000113A/es unknown
- 2012-04-23 CR CR20120197A patent/CR20120197A/es unknown
- 2012-04-25 CL CL2012001055A patent/CL2012001055A1/es unknown
- 2012-04-25 ZA ZA2012/03052A patent/ZA201203052B/en unknown
- 2012-05-18 MA MA34878A patent/MA33758B1/fr unknown
-
2015
- 2015-04-09 US US14/682,176 patent/US20150210767A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2012005024A (es) | 2012-09-07 |
CR20120197A (es) | 2012-06-22 |
KR20120101417A (ko) | 2012-09-13 |
ZA201203052B (en) | 2013-09-25 |
MA33758B1 (fr) | 2012-11-01 |
CA2777312A1 (en) | 2011-05-05 |
TW201125877A (en) | 2011-08-01 |
BR112012010114A2 (pt) | 2017-08-08 |
CN102686239B (zh) | 2016-02-03 |
UY32969A (es) | 2011-05-31 |
DOP2012000113A (es) | 2012-08-15 |
EA201290172A1 (ru) | 2013-04-30 |
JP2013507978A (ja) | 2013-03-07 |
UA107200C2 (uk) | 2014-12-10 |
NZ599114A (en) | 2014-09-26 |
US20150210767A1 (en) | 2015-07-30 |
CL2012001055A1 (es) | 2012-10-05 |
EP2493504A1 (en) | 2012-09-05 |
IL218860A0 (en) | 2012-06-28 |
AU2010311640B2 (en) | 2015-01-29 |
AU2010311640A1 (en) | 2012-05-10 |
ES2552177T3 (es) | 2015-11-26 |
SG10201500274TA (en) | 2015-03-30 |
CN102686239A (zh) | 2012-09-19 |
PE20121564A1 (es) | 2012-11-29 |
CO6612254A2 (es) | 2013-02-01 |
WO2011051217A1 (en) | 2011-05-05 |
EP2493504B1 (en) | 2015-10-07 |
EA022898B1 (ru) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078763A1 (es) | Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas | |
EA201190116A1 (ru) | Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1 | |
CO2017011486A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
AR066848A1 (es) | Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1) | |
CY1120014T1 (el) | Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
AR066849A1 (es) | Polipeptidos, dominios variables de anticuerpos y antagonistas del factor de crecimiento endotelial vascular (vegf) | |
JP2017029157A5 (es) | ||
GT200600389A (es) | Polipeptidos y anticuerpos | |
AR081221A1 (es) | Anticuerpos anti gdf8 humano | |
CR10736A (es) | Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon | |
JP2014169326A5 (es) | ||
NZ602166A (en) | Antibodies to il-6 and use thereof | |
RS54299B1 (en) | COMPOSITIONS AND METHODS OF USING THERAPY ANTIBODIES | |
JP2014522236A5 (es) | ||
AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
CL2012003610A1 (es) | Proteina de union multivalente y multiespecífica que se une al factor de necrosis tumoral (tnf) y al inductor de apoptosis debil relacionado con el factor de necrosis tumoral (tweak); conjugado de union de dicha proteína; acido nucleico que la codifica; vector y célula que comprenden dicho acido nucleico; metodo para producir dicha proteína; composicion farmacéutica que comprende dicha proteína | |
EA201400521A1 (ru) | Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения | |
SG10201903166PA (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
RU2013158083A (ru) | Анти-psgl-1-антитела и их применение | |
CY1121115T1 (el) | Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα | |
ES2556270T3 (es) | Anticuerpos que se fijan a los receptores de la adrenomedulina y sus usos como medicamento | |
JP2014502955A5 (es) | ||
EA201391014A1 (ru) | Способ производства композиции, содержащей местный анестетик, гепариноид и буфер | |
CY1117056T1 (el) | Ιβουπροφαινη για ενδοφλεβια εγχυση |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |